Immatics Announces $125 Million Underwritten Offering for Precision Cancer Treatment

Immatics has agreed to sell 12.5 million ordinary shares at $10.00 per share, raising $125 million in an underwritten offering. The offering is expected to close on December 8, 2025, subject to customary closing conditions. Jefferies, Leerink Partners, and Cantor are acting as joint book-running managers for the offering. The gross proceeds from the offering are expected to be $125 million, before deducting the underwriting discount and offering expenses.